Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology(2025)10.1002/1878-0261.70040Source: DataRank Database

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles is a research paper published in Molecular Oncology (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 0.39)OA: goldTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Sophia M. Orbach ORCID,Kate Griffin ORCID,Ki Sung Kang ORCID,Yining Zhang ORCID,Rebecca S. Pereles

Live enrichment

PubMed:40269509 PMC:PMC12515690 OpenAlex:https://openalex.org/W4409746665

National Institutes of Health

Grant: 1R01AI148076

National Institutes of Health

Grant: 1R01CA243916

National Institutes of Health

Grant: 1R01CA272940

National Institutes of Health

Grant: F32 CA243421

NCI NIH HHS

Grant: P30 CA046592

NCI NIH HHS

Grant: R01 CA243916

NIAID NIH HHS

Grant: R01 AI148076

NCI NIH HHS

Grant: R01 CA272940

FWCI

0.39

Citation Percentile

0.6%

Citation Trend

2026

goldLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.70040

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/1878-0261.70040

publisherhttps://febs.onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.70040

journalhttps://doi.org/10.1002/1878-0261.70040

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40269509

Fields of Study

Immune cells in cancerExtracellular vesicles in diseaseCancer Cells and MetastasisAnimalsNanoparticlesFemaleCell Line, TumorNeoplasm MetastasisMiceLung NeoplasmsMice, Inbred BALB CReceptors, GlucocorticoidCell MovementHumansBreast NeoplasmsImmunomodulationMyeloid CellsCell Proliferation

MeSH Terms

AnimalsBreast NeoplasmsCell MovementFemaleHumansLung NeoplasmsMice, Inbred BALB CNeoplasm MetastasisReceptors, GlucocorticoidMyeloid CellsCell Line, TumorCell ProliferationMiceNanoparticlesImmunomodulation

Keywords

MyeloidCancer researchMetastasisPhenotypeCellBiologyImmunologyTumor microenvironmentCell migrationCancerMedicineTumor cellsNanoparticlesimmunosuppressionMetastatic NicheMyeloid‐derived Suppressor CellsGr1+ Myeloid Cells

Sustainable Development Goals

SDG 0: Good health and well-being

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

FAIR Checklist

Authors (10)

Funding (8 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)